Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 107 entries
Sorted by: Best Match Show Resources per page
A comparative study of methyldopa and labetalol in the treatment of hypertension.

British journal of clinical pharmacology

Sanders GL, Davies DM, Gales GM, Rao JG, Rawlins MD, Routledge PA.
PMID: 26635157
Br J Clin Pharmacol. 1979 Apr;8:149S-51S. doi: 10.1111/j.1365-2125.1979.tb04771.x.

1 Twenty patients with essential hypertension completed a double-blind, dose-tritrated, cross-over comparison of methyldopa and labetalol. 2 Average lying BPs (systolic/diastolic) were reduced by 28/15 mmHg with methyldopa and by 23/15 mmHg with labetalol. 3 Average standing BPs (systolic/diastolic)...

Cite
Sanders GL, Davies DM, Gales GM, et al. A comparative study of methyldopa and labetalol in the treatment of hypertension. Br J Clin Pharmacol. 1979;8:149S-51Sdoi: 10.1111/j.1365-2125.1979.tb04771.x.
Sanders, G. L., Davies, D. M., Gales, G. M., Rao, J. G., Rawlins, M. D., & Routledge, P. A. (1979). A comparative study of methyldopa and labetalol in the treatment of hypertension. British journal of clinical pharmacology, 8149S-51S. https://doi.org/10.1111/j.1365-2125.1979.tb04771.x
Sanders, G L, et al. "A comparative study of methyldopa and labetalol in the treatment of hypertension." British journal of clinical pharmacology vol. 8 (1979): 149S-51S. doi: https://doi.org/10.1111/j.1365-2125.1979.tb04771.x
Sanders GL, Davies DM, Gales GM, Rao JG, Rawlins MD, Routledge PA. A comparative study of methyldopa and labetalol in the treatment of hypertension. Br J Clin Pharmacol. 1979 Apr;8:149S-51S. doi: 10.1111/j.1365-2125.1979.tb04771.x. PMID: 26635157.
Copy Download .nbib Format: NLM
Use of labetalol and methyldopa in pregnancy-induced hypertension.

British journal of clinical pharmacology

Lamming GD, Symonds EB.
PMID: 26635170
Br J Clin Pharmacol. 1979 Apr;8:217S-22S. doi: 10.1111/j.1365-2125.1979.tb04784.x.

1 Nineteen pregnant patients whose mean arterial pressure (MAP) was persistently greater than or equal to 103.3 mmHg were given labetalol or methyldopa. 2 Singificant falls (P less than 0.001) in BP only occurred in the group treated with...

Cite
Lamming GD, Symonds EB. Use of labetalol and methyldopa in pregnancy-induced hypertension. Br J Clin Pharmacol. 1979;8:217S-22Sdoi: 10.1111/j.1365-2125.1979.tb04784.x.
Lamming, G. D., & Symonds, E. B. (1979). Use of labetalol and methyldopa in pregnancy-induced hypertension. British journal of clinical pharmacology, 8217S-22S. https://doi.org/10.1111/j.1365-2125.1979.tb04784.x
Lamming, G D, and Symonds, E B. "Use of labetalol and methyldopa in pregnancy-induced hypertension." British journal of clinical pharmacology vol. 8 (1979): 217S-22S. doi: https://doi.org/10.1111/j.1365-2125.1979.tb04784.x
Lamming GD, Symonds EB. Use of labetalol and methyldopa in pregnancy-induced hypertension. Br J Clin Pharmacol. 1979 Apr;8:217S-22S. doi: 10.1111/j.1365-2125.1979.tb04784.x. PMID: 26635170.
Copy Download .nbib Format: NLM
Autoimmune-like drug-induced liver injury: a review and update for the clinician.

Expert opinion on drug metabolism & toxicology

Stine JG, Northup PG.
PMID: 27402321
Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1291-1301. doi: 10.1080/17425255.2016.1211110. Epub 2016 Jul 21.

INTRODUCTION: Autoimmune-like drug-induced liver injury (DI-AIH) is a rare but serious event with a growing body of scientific evidence and a fair degree of uncertainty. Areas covered: This review covers the definition, pathophysiology, treatment and patient-centered outcomes of DI-AIH...

Cite
Stine JG, Northup PG. Autoimmune-like drug-induced liver injury: a review and update for the clinician. Expert Opin Drug Metab Toxicol. 2016;12(11):1291-1301doi: 10.1080/17425255.2016.1211110.
Stine, J. G., & Northup, P. G. (2016). Autoimmune-like drug-induced liver injury: a review and update for the clinician. Expert opinion on drug metabolism & toxicology, 12(11), 1291-1301. https://doi.org/10.1080/17425255.2016.1211110
Stine, Jonathan G, and Northup, Patrick G. "Autoimmune-like drug-induced liver injury: a review and update for the clinician." Expert opinion on drug metabolism & toxicology vol. 12,11 (2016): 1291-1301. doi: https://doi.org/10.1080/17425255.2016.1211110
Stine JG, Northup PG. Autoimmune-like drug-induced liver injury: a review and update for the clinician. Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1291-1301. doi: 10.1080/17425255.2016.1211110. Epub 2016 Jul 21. PMID: 27402321.
Copy Download .nbib Format: NLM
Antihypertensive drug prescription pattern before and during pregnancy in France.

Pregnancy hypertension

Duhalde V, Delarue C, Lacroix I, Suarez C, Bourrel R, Montastruc JL, Damase-Michel C.
PMID: 26104501
Pregnancy Hypertens. 2011 Apr;1(2):185-9. doi: 10.1016/j.preghy.2011.01.001. Epub 2011 Feb 01.

OBJECTIVE: This study provides firsthand information on antihypertensive prescriptions before and during pregnancy in France.METHODS: The study, on 23,898 women, was carried out using data from the French Health Insurance System.RESULTS: Before and during pregnancy, 1.1% and 5.1% of...

Cite
Duhalde V, Delarue C, Lacroix I, et al. Antihypertensive drug prescription pattern before and during pregnancy in France. Pregnancy Hypertens. 2011;1(2):185-9doi: 10.1016/j.preghy.2011.01.001.
Duhalde, V., Delarue, C., Lacroix, I., Suarez, C., Bourrel, R., Montastruc, J. L., & Damase-Michel, C. (2011). Antihypertensive drug prescription pattern before and during pregnancy in France. Pregnancy hypertension, 1(2), 185-9. https://doi.org/10.1016/j.preghy.2011.01.001
Duhalde, Veronique, et al. "Antihypertensive drug prescription pattern before and during pregnancy in France." Pregnancy hypertension vol. 1,2 (2011): 185-9. doi: https://doi.org/10.1016/j.preghy.2011.01.001
Duhalde V, Delarue C, Lacroix I, Suarez C, Bourrel R, Montastruc JL, Damase-Michel C. Antihypertensive drug prescription pattern before and during pregnancy in France. Pregnancy Hypertens. 2011 Apr;1(2):185-9. doi: 10.1016/j.preghy.2011.01.001. Epub 2011 Feb 01. PMID: 26104501.
Copy Download .nbib Format: NLM
NTP Toxicology and Carcinogenesis Studies of alpha-Methyldopa Sesquihydrate (CAS No. 41372-08-1) in F344/N Rats and B6C3F1 Mice (Feed Studies).

National Toxicology Program technical report series

[No authors listed]
PMID: 12704436
Natl Toxicol Program Tech Rep Ser. 1989 Mar;348:1-184.

a-Methyldopa sesquihydrate is used in the treatment of hypertension; over 20 million prescriptions are written annually for a -methyldopa or a-methyldopa sesquihydrate in the United States. a-Methyldopa sesquihydrate (USP grade, greater than 99% pure) was selected for study because...

Cite
NTP Toxicology and Carcinogenesis Studies of alpha-Methyldopa Sesquihydrate (CAS No. 41372-08-1) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser. 1989;348:1-184
(1989). NTP Toxicology and Carcinogenesis Studies of alpha-Methyldopa Sesquihydrate (CAS No. 41372-08-1) in F344/N Rats and B6C3F1 Mice (Feed Studies). National Toxicology Program technical report series, 3481-184.
"NTP Toxicology and Carcinogenesis Studies of alpha-Methyldopa Sesquihydrate (CAS No. 41372-08-1) in F344/N Rats and B6C3F1 Mice (Feed Studies)." National Toxicology Program technical report series vol. 348 (1989): 1-184.
NTP Toxicology and Carcinogenesis Studies of alpha-Methyldopa Sesquihydrate (CAS No. 41372-08-1) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser. 1989 Mar;348:1-184. PMID: 12704436.
Copy Download .nbib Format: NLM
A sensitive and selective spectrophotometric estimation of catechol derivatives in pharmaceutical preparations.

Talanta

Nagaraja P, Vasantha RA, Sunitha KR.
PMID: 18968454
Talanta. 2001 Dec 24;55(6):1039-46. doi: 10.1016/s0039-9140(01)00438-6.

A sensitive and simple spectrophotometric method for the estimation of catechol and its derivatives like dopamine hydrochloride (DPH), levodopa (LDP), methyldopa (MDP) and adrenaline hydrochloride (ADH) in both pure form and in pharmaceutical formulation, is described. The method is...

Cite
Nagaraja P, Vasantha RA, Sunitha KR. A sensitive and selective spectrophotometric estimation of catechol derivatives in pharmaceutical preparations. Talanta. 2001;55(6):1039-46doi: 10.1016/s0039-9140(01)00438-6.
Nagaraja, P., Vasantha, R. A., & Sunitha, K. R. (2001). A sensitive and selective spectrophotometric estimation of catechol derivatives in pharmaceutical preparations. Talanta, 55(6), 1039-46. https://doi.org/10.1016/s0039-9140(01)00438-6
Nagaraja, P, et al. "A sensitive and selective spectrophotometric estimation of catechol derivatives in pharmaceutical preparations." Talanta vol. 55,6 (2001): 1039-46. doi: https://doi.org/10.1016/s0039-9140(01)00438-6
Nagaraja P, Vasantha RA, Sunitha KR. A sensitive and selective spectrophotometric estimation of catechol derivatives in pharmaceutical preparations. Talanta. 2001 Dec 24;55(6):1039-46. doi: 10.1016/s0039-9140(01)00438-6. PMID: 18968454.
Copy Download .nbib Format: NLM
Methyldopa-induced thrombocytopenia.

Canadian Medical Association journal

Ten Pas A, de Leeuw NK, Stacey CH.
PMID: 20328626
Can Med Assoc J. 1966 Aug 13;95(7):322.

No abstract available.

Cite
Ten Pas A, de Leeuw NK, Stacey CH. Methyldopa-induced thrombocytopenia. Can Med Assoc J. 1966;95(7):322
Ten Pas, A., de Leeuw, N. K., & Stacey, C. H. (1966). Methyldopa-induced thrombocytopenia. Canadian Medical Association journal, 95(7), 322.
Ten Pas, A, et al. "Methyldopa-induced thrombocytopenia." Canadian Medical Association journal vol. 95,7 (1966): 322.
Ten Pas A, de Leeuw NK, Stacey CH. Methyldopa-induced thrombocytopenia. Can Med Assoc J. 1966 Aug 13;95(7):322. PMID: 20328626; PMCID: PMC1935583.
Copy Download .nbib Format: NLM
Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo).

Neuropsychiatric disease and treatment

Solla P, Cannas A, Marrosu F, Marrosu MG.
PMID: 20856911
Neuropsychiatr Dis Treat. 2010 Sep 07;6:483-90. doi: 10.2147/ndt.s5190.

Parkinson disease (PD) is a neurodegenerative disorder characterized by 3 cardinal motor symptoms: resting tremor, rigidity, and bradykinesia. Since its introduction 40 years ago, levodopa has represented the gold standard for dopaminergic stimulation therapy in patients with PD. Levodopa...

Cite
Solla P, Cannas A, Marrosu F, et al. Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). Neuropsychiatr Dis Treat. 2010;6:483-90doi: 10.2147/ndt.s5190.
Solla, P., Cannas, A., Marrosu, F., & Marrosu, M. G. (2010). Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). Neuropsychiatric disease and treatment, 6483-90. https://doi.org/10.2147/ndt.s5190
Solla, Paolo, et al. "Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo)." Neuropsychiatric disease and treatment vol. 6 (2010): 483-90. doi: https://doi.org/10.2147/ndt.s5190
Solla P, Cannas A, Marrosu F, Marrosu MG. Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). Neuropsychiatr Dis Treat. 2010 Sep 07;6:483-90. doi: 10.2147/ndt.s5190. PMID: 20856911; PMCID: PMC2938297.
Copy Download .nbib Format: NLM
The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism.

British journal of clinical pharmacology

Bergmann S, Curzon G, Friedel J, Godwin-Austen RB, Marsden CD, Parkes JD.
PMID: 22454921
Br J Clin Pharmacol. 1974 Oct;1(5):417-24. doi: 10.1111/j.1365-2125.1974.tb00280.x.

1 The metabolism of a standard oral dose of levodopa was studied in forty-two patients with Parkinsonism. Plasma levodopa and 3-o-methyldopa concentrations were estimated at intervals for 8 h after ingestion and the concentration of homovanillic acid (HVA) in...

Cite
Bergmann S, Curzon G, Friedel J, et al. The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism. Br J Clin Pharmacol. 1974;1(5):417-24doi: 10.1111/j.1365-2125.1974.tb00280.x.
Bergmann, S., Curzon, G., Friedel, J., Godwin-Austen, R. B., Marsden, C. D., & Parkes, J. D. (1974). The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism. British journal of clinical pharmacology, 1(5), 417-24. https://doi.org/10.1111/j.1365-2125.1974.tb00280.x
Bergmann, S, et al. "The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism." British journal of clinical pharmacology vol. 1,5 (1974): 417-24. doi: https://doi.org/10.1111/j.1365-2125.1974.tb00280.x
Bergmann S, Curzon G, Friedel J, Godwin-Austen RB, Marsden CD, Parkes JD. The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism. Br J Clin Pharmacol. 1974 Oct;1(5):417-24. doi: 10.1111/j.1365-2125.1974.tb00280.x. PMID: 22454921; PMCID: PMC1402477.
Copy Download .nbib Format: NLM
A new spectrophotometric method for the determination of methyldopa.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

Gadkariem EA, Ibrahim KE, Kamil NA, Haga ME, El-Obeid HA.
PMID: 23960712
Saudi Pharm J. 2009 Oct;17(4):289-93. doi: 10.1016/j.jsps.2009.10.005. Epub 2009 Nov 10.

A new, simple and low cost spectrophotometric method for the determination of methyldopa in pharmaceutical preparations was developed. The method was based on the coupling of methyldopa with 2,6-dichloroquinone-4-chlorimide (DCQ). The absorbance maximum (λ max) of the resulted colored...

Cite
Gadkariem EA, Ibrahim KE, Kamil NA, et al. A new spectrophotometric method for the determination of methyldopa. Saudi Pharm J. 2009;17(4):289-93doi: 10.1016/j.jsps.2009.10.005.
Gadkariem, E. A., Ibrahim, K. E., Kamil, N. A., Haga, M. E., & El-Obeid, H. A. (2009). A new spectrophotometric method for the determination of methyldopa. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 17(4), 289-93. https://doi.org/10.1016/j.jsps.2009.10.005
Gadkariem, E A, et al. "A new spectrophotometric method for the determination of methyldopa." Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society vol. 17,4 (2009): 289-93. doi: https://doi.org/10.1016/j.jsps.2009.10.005
Gadkariem EA, Ibrahim KE, Kamil NA, Haga ME, El-Obeid HA. A new spectrophotometric method for the determination of methyldopa. Saudi Pharm J. 2009 Oct;17(4):289-93. doi: 10.1016/j.jsps.2009.10.005. Epub 2009 Nov 10. PMID: 23960712; PMCID: PMC3730969.
Copy Download .nbib Format: NLM
Comparison of atenolol (tenormin) and methyldopa (a multicentre study in general practice).

Proceedings of the Royal Society of Medicine

Basker MA.
PMID: 20919337
Proc R Soc Med. 1977;70:19-20.

No abstract available.

Cite
Basker MA. Comparison of atenolol (tenormin) and methyldopa (a multicentre study in general practice). Proc R Soc Med. 1977;70:19-20
Basker, M. A. (1977). Comparison of atenolol (tenormin) and methyldopa (a multicentre study in general practice). Proceedings of the Royal Society of Medicine, 7019-20.
Basker, M A. "Comparison of atenolol (tenormin) and methyldopa (a multicentre study in general practice)." Proceedings of the Royal Society of Medicine vol. 70 (1977): 19-20.
Basker MA. Comparison of atenolol (tenormin) and methyldopa (a multicentre study in general practice). Proc R Soc Med. 1977;70:19-20. PMID: 20919337; PMCID: PMC1542851.
Copy Download .nbib Format: NLM
Adverse drug reactions in high-risk pregnant women: A prospective study.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

de Oliveira-Filho AD, Vieira AES, da Silva RC, Neves SJF, Gama TAB, Lima RV, Oliveira WR, de Gonçalves Dias JM.
PMID: 29158717
Saudi Pharm J. 2017 Nov;25(7):1073-1077. doi: 10.1016/j.jsps.2017.01.005. Epub 2017 Feb 02.

BACKGROUND: Because pregnant women are often excluded from clinical trials, there is still very limited information about the risk and safety of prescription drugs during pregnancy.OBJECTIVE: We aimed to determine the prevalence of Adverse Drug Reactions (ADRs) in high-risk...

Cite
de Oliveira-Filho AD, Vieira AES, da Silva RC, et al. Adverse drug reactions in high-risk pregnant women: A prospective study. Saudi Pharm J. 2017;25(7):1073-1077doi: 10.1016/j.jsps.2017.01.005.
de Oliveira-Filho, A. D., Vieira, A. E. S., da Silva, R. C., Neves, S. J. F., Gama, T. A. B., Lima, R. V., Oliveira, W. R., & de Gonçalves Dias, J. M. (2017). Adverse drug reactions in high-risk pregnant women: A prospective study. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 25(7), 1073-1077. https://doi.org/10.1016/j.jsps.2017.01.005
de Oliveira-Filho, Alfredo Dias, et al. "Adverse drug reactions in high-risk pregnant women: A prospective study." Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society vol. 25,7 (2017): 1073-1077. doi: https://doi.org/10.1016/j.jsps.2017.01.005
de Oliveira-Filho AD, Vieira AES, da Silva RC, Neves SJF, Gama TAB, Lima RV, Oliveira WR, de Gonçalves Dias JM. Adverse drug reactions in high-risk pregnant women: A prospective study. Saudi Pharm J. 2017 Nov;25(7):1073-1077. doi: 10.1016/j.jsps.2017.01.005. Epub 2017 Feb 02. PMID: 29158717; PMCID: PMC5681315.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 107 entries